Update: May 30, 2021 10:01 PM STI
Colombo [Sri Lanka], May 30 (ANI): The disclosure of the purchase price of China’s Sinopharm vaccine in Sri Lanka sparked a row after reports revealed Colombo had to shell out a higher price per dose than its compatriot, Bangladesh, the country of Sri Lanka. ‘South Asia.
Sri Lanka is paying $ 15 per dose for the Sinopharm vaccine, according to The Daily Star, which is $ 5 more than Bangladesh paid.
Contrary to media reports, Channa Jayasuma, the country’s state professor of pharmaceutical supply and regulation, said there was “no such deal to give the vaccine to 10 USD for Bangladesh “.
The minister said he had been informed by the Chinese embassy and the Sinopharm company that there was no such deal to give the vaccine at USD 10 for Bangladesh.
Jayasuma’s claims contrast with what Bangladesh Finance Minister AHM Mustafa Kamal, an official in the Cabinet division, said earlier this week that Dhaka was buying the vaccine at $ 10 per dose.
Meanwhile, Sri Lanka’s director general of health services, Dr Asela Gunawardena, also defended the government’s purchase price, saying they got the Sinopharm vaccines at minimum cost.
“We bought the vaccines at the minimum cost we could and at a competitive price,” he said. “Prices for COVID-19 vaccines range from $ 18 to $ 40. Prices are subject to change for many reasons ”, underlined DG Health.
Besides Sri Lanka, the government of Bangladesh has also approved the purchase of millions of doses of the COVID-19 vaccine from China. From June, shipments will arrive in Bangladesh in three phases, with five million doses in each shipment, bdnews24 reported.
Bangladesh had started its coronavirus vaccination campaign with the Oxford-AstraZeneca vaccine purchased from India at $ 5 per dose. As it stands, the Chinese vaccine will cost Bangladesh twice as much as the Oxford-AstraZeneca vaccine from Serum India of India.
Similarly, Sri Lanka reportedly bought a dose of AstraZeneca vaccine for US $ 5.50, almost a third of the price offered by Beijing. (ANI)